Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension
研究概览
简要总结
The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.
详细描述
Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically indicated right heart catheterization may be enrolled. Clinical data and blood samples will be analyzed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old
- •Undergoing RHC for PH evaluation
排除标准
- •Anemia defined as Hgb < 10 g/dL and HCT < 30
- •Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day of the procedure)
- •Left ventricular ejection fraction ≤ 40%
- •Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on the day of the procedure)
- •IPF, CTEPH, COPD/OSA as the dominant etiology of PH
- •Patient is currently taking PH medication or long-acting nitrates at the time of their RHC.
研究组 & 干预措施
Pulmonary Hypertension & WHO group I
Participants with Pulmonary Hypertension with a WHO classification group I and are scheduled to have a right heart catheterization.
Pulmonary Hypertension & WHO group II
Participants with Pulmonary Hypertension with a WHO classification group II and are scheduled to have a right heart catheterization.
Without Pulmonary Hypertension
Participants without Pulmonary Hypertension
Connective Tissue Disease
Participants without PH, but with connective tissue disease
结局指标
主要结局
Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension
时间窗: At baseline
次要结局
- Vasodilator-induced changes in Pulmonary Hypertension biomarkers(At baseline)
- Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR)(At baseline)
研究者
Ken Monahan
Assistant Professor
Vanderbilt University